Advertisement

Drugs

, Volume 79, Issue 5, pp 515–529 | Cite as

Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke

  • Ming Yang
  • Xiaochuan Huo
  • Zhongrong Miao
  • Yongjun WangEmail author
Review Article

Abstract

Tirofiban is a non-peptide selective glycoprotein (GP) IIb/IIIa receptor inhibitor that reversibly inhibits fibrinogen-dependent platelet aggregation and subsequent formation of thrombi, which contribute to the major atherosclerotic complications in the development, progression, and resolution of ischemic stroke. The adjunctive use of tirofiban has been extensively evaluated in progressive stroke, combined intravenous thrombolysis (IVT), and endovascular treatment (EVT) in both preclinical and clinical studies. A body of evidence has been accumulated on the risks and benefits associated with tirofiban in terms of prevention of stroke progression, stent thrombosis, improvement in functional independence, and mortality, especially among high-risk ischemic stroke patients as a further strategy alongside conventional treatment. In general, tirofiban has a favorable tolerability and efficacy profile in the improvement of vascular recanalization and long-term functional outcome, although the optimum dosage, application setting, and precise target patients are not yet well-established. However, its specific inhibition of ongoing platelet aggregation and thrombus formation rather than absolute thrombolysis suggests that tirofiban, one of the most widely used GP IIb/IIIa inhibitors, with high affinity and a short plasma/biologic half-life, may have great potential in the acute treatment of ischemic stroke. Substantial practical progress is likely as our understanding of the mechanism of action and pharmacological actions of tirofiban in atherosclerotic ischemic disease improves. Therefore, we classify and summarize the available findings regarding tirofiban in acute ischemic stroke to stimulate and guide further research and clinical practice.

Notes

Compliance with Ethical Standards

Funding

This study was supported by a grant from National Key R&D Program of China (grant number: 2016YFC1301500) and National Science and Technology Major Project of China (grant number: 2015BAI12B02 and 2017YFC1310901).

Conflict of interest

Ming Yang, Xiaochuan Huo, Zhongrong Miao and Yongjun Wang have no conflicts of interest that are directly relevant to the contents of this article.

References

  1. 1.
    Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104:1606–15.CrossRefPubMedGoogle Scholar
  2. 2.
    Murugappan S, Shankar H, Kunapuli SP. Platelet receptors for adenine nucleotides and thromboxane a2. Semin Thromb Hemost. 2004;30:411–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, et al. Conformation-specific blockade of the integrin gpiib/iiia: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res. 2006;99:25–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein iib/iiia receptor with tirofiban in unstable angina and non-q-wave myocardial infarction. N Engl J Med. 1998;338:1488–1497.Google Scholar
  5. 5.
    Ali A, Hashem M, Rosman HS, Moser L, Rehan A, Davis T, et al. Glycoprotein iib/iiia receptor antagonists and risk of bleeding: a single-center experience in 1020 patients. J Clin Pharmacol. 2004;44:1328–32.CrossRefPubMedGoogle Scholar
  6. 6.
    Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, et al. Mk-383 (l-700,462), a selective nonpeptide platelet glycoprotein iib/iiia antagonist, is active in man. Circulation. 1993;88:1512–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein iib-iiia complex. Blood. 1988;71:831–43.PubMedGoogle Scholar
  8. 8.
    Ishikawa T, Shimizu M, Kohara S, Takizawa S, Kitagawa Y, Takagi S. Appearance of wbc-platelet complex in acute ischemic stroke, predominantly in atherothrombotic infarction. J Atheroscler Thromb. 2012;19:494–501.CrossRefPubMedGoogle Scholar
  9. 9.
    Coller BS. Anti-gpiib/iiia drugs: current strategies and future directions. Thromb Haemost. 2001;86:427–43.CrossRefPubMedGoogle Scholar
  10. 10.
    Radke PW, Janssens U, Schwarz ER, vom Dahl J. Therapeutic dissolution of an intracoronary thrombus by prolonged intravenous platelet glycoprotein iib/iiia antagonism. J Invas Cardiol. 1999;11:679–81.Google Scholar
  11. 11.
    Sarullo FM, Pasquale PD, D’Alfonso G, Amerigo L, Cannizzaro S, Castello A. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings. Italian Heart J. 2001;2:605–11.Google Scholar
  12. 12.
    Umemura K, Kondo K, Ikeda Y, Nakashima M. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein iib/iiia inhibitor tirofiban. Thromb Haemost. 1997;78:1381–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, et al. Pharmacokinetics and pharmacodynamics of mk-383, a selective non-peptide platelet glycoprotein-iib/iiia receptor antagonist, in healthy men. Clin Pharmacol Ther. 1994;56:377–88.CrossRefPubMedGoogle Scholar
  14. 14.
    McClellan KJ, Goa KL. Tirofiban. A review of its use in acute coronary syndromes. Drugs. 1998;56:1067–1080.Google Scholar
  15. 15.
    Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, et al. Integrin alpha(iib)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke. 2000;31:1402–1409 (discussion 1409–1410).Google Scholar
  16. 16.
    Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet gpiib/iiia receptor. Correlation with bleeding time, platelet aggregation, and blockade of gpiib/iiia receptors. Circulation. 1989;80:1766–1774.Google Scholar
  17. 17.
    Choudhri TF, Hoh BL, Zerwes HG, Prestigiacomo CJ, Kim SC, Connolly ES Jr, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting gp iib/iiia receptor-mediated platelet aggregation. J Clin Investig. 1998;102:1301–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002;87:1020–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha iib beta 3 (gpiib/iiia) antagonists, c7e3 and dmp728. Thromb Res. 1997;88:137–46.CrossRefPubMedGoogle Scholar
  20. 20.
    Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7e3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation. 1997;95:1755–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Shuaib A, Yang Y, Nakada MT, Li Q, Yang T. Glycoprotein iib/iiia antagonist, murine 7e3 f(ab’) 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy. J Cereb Blood Flow Metab. 2002;22:215–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Ding G, Jiang Q, Zhang L, Zhang ZG, Li L, Knight RA, et al. Analysis of combined treatment of embolic stroke in rat with r-tpa and a gpiib/iiia inhibitor. J Cereb Blood Flow Metab. 2005;25:87–97.CrossRefPubMedGoogle Scholar
  23. 23.
    Feng L, Liu J, Liu Y, Chen J, Su C, Lv C, et al. Tirofiban combined with urokinase selective intra-arterial thrombolysis for the treatment of middle cerebral artery occlusion. Exp Ther Med. 2016;11:1011–6.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Baik SK, Oh SJ, Park KP, Lee JH. Intra-arterial tirofiban infusion for partial recanalization with stagnant flow in hyperacute cerebral ischemic stroke. Interv Neuroradiol. 2011;17:442–51.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Jeong HW, Jin SC. Intra-arterial infusion of a glycoprotein iib/iiia antagonist for the treatment of thromboembolism during coil embolization of intracranial aneurysm: a comparison of abciximab and tirofiban. AJNR. 2013;34:1621–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Birschel P, Ellul J, Barer D. Progressing stroke: towards an internationally agreed definition. Cerebrovasc Dis. 2004;17:242–52.CrossRefPubMedGoogle Scholar
  28. 28.
    D’Olhaberriague L, Litvan I, Mitsias P, Mansbach HH. A reappraisal of reliability and validity studies in stroke. Stroke. 1996;27:2331–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Moon HS, Kim YB, Suh BC, Won YS, Park KY, Chung PW. Association of initial infarct extent and progressive motor deficits in striatocapsular infarction. J Clin Neurol (Seoul, Korea). 2008;4:111–5.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Jeong HG, Kim BJ, Yang MH, Han MK, Bae HJ. Neuroimaging markers for early neurologic deterioration in single small subcortical infarction. Stroke. 2015;46:687–91.CrossRefPubMedGoogle Scholar
  31. 31.
    Kim SK, Song P, Hong JM, Pak CY, Chung CS, Lee KH, et al. Prediction of progressive motor deficits in patients with deep subcortical infarction. Cerebrovasc Dis. 2008;25:297–303.CrossRefPubMedGoogle Scholar
  32. 32.
    Junghans U, Seitz RJ, Aulich A, Freund HJ, Siebler M. Bleeding risk of tirofiban, a nonpeptide gpiib/iiia platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis. 2001;12:308–12.CrossRefPubMedGoogle Scholar
  33. 33.
    Philipps J, Thomalla G, Glahn J, Schwarze M, Rother J. Treatment of progressive stroke with tirofiban–experience in 35 patients. Cerebrovasc Dis. 2009;28:435–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Steinke W, Ley SC. Lacunar stroke is the major cause of progressive motor deficits. Stroke. 2002;33:1510–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Torgano G, Zecca B, Monzani V, Maestroni A, Rossi P, Cazzaniga M, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. Cerebrovasc Dis. 2010;29:275–81.CrossRefPubMedGoogle Scholar
  36. 36.
    Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, Rother J, et al. Safety of tirofiban in acute ischemic stroke: the satis trial. Stroke. 2011;42:2388–92.CrossRefPubMedGoogle Scholar
  37. 37.
    Caplan LR, Hennerici M. Impaired clearance of emboli (washout) is an important link between hypoperfusion, embolism, and ischemic stroke. Arch Neurol. 1998;55:1475–82.CrossRefPubMedGoogle Scholar
  38. 38.
    Schreiber S, Serdaroglu M, Schreiber F, Skalej M, Heinze HJ, Goertler M. Simultaneous occurrence and interaction of hypoperfusion and embolism in a patient with severe middle cerebral artery stenosis. Stroke. 2009;40:e478–80.CrossRefPubMedGoogle Scholar
  39. 39.
    Junghans U, Siebler M. Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein iib/iiia receptor antagonist. Circulation. 2003;107:2717–21.CrossRefPubMedGoogle Scholar
  40. 40.
    NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.CrossRefGoogle Scholar
  41. 41.
    Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329.Google Scholar
  42. 42.
    Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:967–73.CrossRefPubMedGoogle Scholar
  43. 43.
    Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59:862–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Rubiera M, Alvarez-Sabin J, Ribo M, Montaner J, Santamarina E, Arenillas JF, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005;36:1452–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Heo JH, Lee KY, Kim SH, Kim DI. Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology. 2003;60:1684–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Saqqur M, Molina CA, Salam A, Siddiqui M, Ribo M, Uchino K, et al. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial doppler study. Stroke. 2007;38:69–74.CrossRefPubMedGoogle Scholar
  47. 47.
    Zinkstok SM, Roos YB. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet (London, England). 2012;380:731–7.CrossRefGoogle Scholar
  48. 48.
    Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, et al. The combined approach to lysis utilizing eptifibatide and rt-pa in acute ischemic stroke: the clear stroke trial. Stroke. 2008;39:3268–76.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2013;44:870–947.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Diedler J, Ahmed N, Sykora M, Uyttenboogaart M, Overgaard K, Luijckx GJ, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41:288–94.CrossRefPubMedGoogle Scholar
  51. 51.
    Amaro S, Llull L, Urra X, Obach V, Cervera A, Chamorro A. Risks and benefits of early antithrombotic therapy after thrombolytic treatment in patients with acute stroke. PLoS One. 2013;8:e71132.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Pancioli AM, Adeoye O, Schmit PA, Khoury J, Levine SR, Tomsick TA, et al. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke. 2013;44:2381–7.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Adeoye O, Sucharew H, Khoury J, Vagal A, Schmit PA, Ewing I, et al. Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator in acute ischemic stroke-full dose regimen stroke trial. Stroke. 2015;46:2529–33.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Seitz RJ, Hamzavi M, Junghans U, Ringleb PA, Schranz C, Siebler M. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations. Stroke. 2003;34:1932–5.CrossRefPubMedGoogle Scholar
  55. 55.
    Junghans U, Seitz RJ, Wittsack HJ, Aulich A, Siebler M. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein iib/iiia inhibitor: report of four cases. Radiology. 2001;221:795–801.CrossRefPubMedGoogle Scholar
  56. 56.
    Seitz RJ, Meisel S, Moll M, Wittsack HJ, Junghans U, Siebler M. The effect of combined thrombolysis with rtpa and tirofiban on ischemic brain lesions. Neurology. 2004;62:2110–2.CrossRefPubMedGoogle Scholar
  57. 57.
    Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke. 2004;35:705–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Li W, Lin L, Zhang M, Wu Y, Liu C, Li X, et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients. Stroke. 2016;47:2649–51.CrossRefPubMedGoogle Scholar
  59. 59.
    Becker R. Dynamics of coronary thrombolysis and reocclusion. Clin Cardiol. 1997;20:Iii2–5.Google Scholar
  60. 60.
    Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol. 1992;19:926–35.CrossRefPubMedGoogle Scholar
  61. 61.
    Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996;93:229–37.CrossRefPubMedGoogle Scholar
  62. 62.
    Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res. 2004;114:447–53.CrossRefPubMedGoogle Scholar
  63. 63.
    Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L’Allier PL, Ziada KM, et al. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein iib/iiia inhibition in complex atherosclerotic lesions. Circulation. 2000;102:28–34.CrossRefPubMedGoogle Scholar
  64. 64.
    Casserly IP, Topol EJ. Glycoprotein iib/iiia antagonists–from bench to practice. CMLS. 2002;59:478–500.CrossRefPubMedGoogle Scholar
  65. 65.
    Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957–66.CrossRefPubMedGoogle Scholar
  66. 66.
    Steen H, Lehrke S, Wiegand UK, Merten C, Schuster L, Richardt G, et al. Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for st-elevation myocardial infarction. Am Heart J. 2005;149:564.CrossRefPubMedGoogle Scholar
  67. 67.
    Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 esc/eacts guidelines on myocardial revascularization: the task force on myocardial revascularization of the european society of cardiology (esc) and the european association for cardio-thoracic surgery (eacts)developed with the special contribution of the european association of percutaneous cardiovascular interventions (eapci). Eur Heart J. 2014;35:2541–619.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. 2015 american heart association/american stroke association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2015;46:3020–35.CrossRefPubMedGoogle Scholar
  69. 69.
    Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2018;49:e46–110.CrossRefPubMedGoogle Scholar
  70. 70.
    Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368:914–23.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–30.CrossRefPubMedGoogle Scholar
  72. 72.
    Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296–306.CrossRefPubMedGoogle Scholar
  73. 73.
    Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–18.CrossRefPubMedGoogle Scholar
  74. 74.
    Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-pa vs. T-pa alone in stroke. N Engl J Med. 2015;372:2285–2295.Google Scholar
  75. 75.
    Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11–21.CrossRefPubMedGoogle Scholar
  76. 76.
    Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708–18.CrossRefPubMedGoogle Scholar
  77. 77.
    Teng D, Pannell JS, Rennert RC, Li J, Li YS, Wong VW, et al. Endothelial trauma from mechanical thrombectomy in acute stroke: in vitro live-cell platform with animal validation. Stroke. 2015;46:1099–106.CrossRefPubMedGoogle Scholar
  78. 78.
    Power S, Matouk C, Casaubon LK, Silver FL, Krings T, Mikulis DJ, et al. Vessel wall magnetic resonance imaging in acute ischemic stroke: effects of embolism and mechanical thrombectomy on the arterial wall. Stroke. 2014;45:2330–4.CrossRefPubMedGoogle Scholar
  79. 79.
    Qureshi AI, Hussein HM, Abdelmoula M, Georgiadis AL, Janjua N. Subacute recanalization and reocclusion in patients with acute ischemic stroke following endovascular treatment. Neurocrit Care. 2009;10:195–203.CrossRefPubMedGoogle Scholar
  80. 80.
    Mangiafico S, Cellerini M, Nencini P, Gensini G, Inzitari D. Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases. Stroke. 2005;36:2154–8.CrossRefPubMedGoogle Scholar
  81. 81.
    Mangiafico S, Cellerini M, Nencini P, Gensini G, Inzitari D. Intravenous glycoprotein iib/iiia inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke. AJNR. 2005;26:2595–601.PubMedGoogle Scholar
  82. 82.
    Ihn YK, Sung JH, Kim BS. Intravenous glycoprotein iib/iiia inhibitor (tirofiban) followed by low-dose intra-arterial urokinase and mechanical thrombolysis for the treatment of acute stroke. Neuroradiol J. 2011;24:907–13.CrossRefPubMedGoogle Scholar
  83. 83.
    Ernst M, Butscheid F, Fiehler J, Wittkugel O, Alfke K, Jansen O, et al. Glycoprotein iib/iiia inhibitor bridging and subsequent endovascular therapy in vertebrobasilar occlusion in 120 patients. Clin Neuroradiol. 2016;26:169–75.CrossRefPubMedGoogle Scholar
  84. 84.
    Savitz SI, Caplan LR. Vertebrobasilar disease. N Engl J Med. 2005;352:2618–26.CrossRefPubMedGoogle Scholar
  85. 85.
    Nagel S, Schellinger PD, Hartmann M, Juettler E, Huttner HB, Ringleb P, et al. Therapy of acute basilar artery occlusion: intraarterial thrombolysis alone vs bridging therapy. Stroke. 2009;40:140–6.CrossRefPubMedGoogle Scholar
  86. 86.
    Schonewille WJ, Wijman CA, Michel P, Rueckert CM, Weimar C, Mattle HP, et al. Treatment and outcomes of acute basilar artery occlusion in the basilar artery international cooperation study (basics): a prospective registry study. Lancet Neurol. 2009;8:724–30.CrossRefPubMedGoogle Scholar
  87. 87.
    Giray S, Ozdemir O, Bas DF, Inanc Y, Arlier Z, Kocaturk O. Does stroke etiology play a role in predicting outcome of acute stroke patients who underwent endovascular treatment with stent retrievers? J Neurol Sci. 2017;372:104–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Lapergue B, Blanc R, Gory B, Labreuche J, Duhamel A, Marnat G, et al. Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: the aster randomized clinical trial. JAMA. 2017;318:443–52.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Kang DH, Kim YW, Hwang YH, Park SP, Kim YS, Baik SK. Instant reocclusion following mechanical thrombectomy of in situ thromboocclusion and the role of low-dose intra-arterial tirofiban. Cerebrovasc Dis. 2014;37:350–5.CrossRefPubMedGoogle Scholar
  90. 90.
    Kurre W, Aguilar-Perez M, Schmid E, Sperber W, Bazner H, Henkes H. Clinical experience with the preset stent retriever for the treatment of acute ischemic stroke–a review of 271 consecutive cases. Neuroradiology. 2014;56:397–403.CrossRefPubMedGoogle Scholar
  91. 91.
    Baek JH, Kim BM, Kim DJ, Heo JH, Nam HS, Yoo J. Stenting as a rescue treatment after failure of mechanical thrombectomy for anterior circulation large artery occlusion. Stroke. 2016;47:2360–3.CrossRefPubMedGoogle Scholar
  92. 92.
    Klisch J, Sychra V, Strasilla C, Taschner CA, Reinhard M, Urbach H, et al. Double solitaire mechanical thrombectomy in acute stroke: effective rescue strategy for refractory artery occlusions? AJNR. 2015;36:552–6.CrossRefPubMedGoogle Scholar
  93. 93.
    Chang Y, Kim BM, Bang OY, Baek JH, Heo JH, Nam HS, et al. Rescue stenting for failed mechanical thrombectomy in acute ischemic stroke: a multicenter experience. Stroke. 2018;49:958–64.CrossRefPubMedGoogle Scholar
  94. 94.
    Kwon OK, Lee KJ, Han MH, Oh CW, Han DH, Koh YC. Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases. AJNR. 2002;23:447–51.PubMedGoogle Scholar
  95. 95.
    Deshmukh VR, Fiorella DJ, Albuquerque FC, Frey J, Flaster M, Wallace RC, et al. Intra-arterial thrombolysis for acute ischemic stroke: Preliminary experience with platelet glycoprotein iib/iiia inhibitors as adjunctive therapy. Neurosurgery. 2005;56:46–54 (discussion 54–45).Google Scholar
  96. 96.
    Kwon JH, Shin SH, Weon YC, Hwang JC, Baik SK. Intra-arterial adjuvant tirofiban after unsuccessful intra-arterial thrombolysis of acute ischemic stroke: preliminary experience in 16 patients. Neuroradiology. 2011;53:779–85.CrossRefPubMedGoogle Scholar
  97. 97.
    Kim JW, Jeon P, Kim GM, Bang OY, Byun HS, Kim KH. Local intraarterial tirofiban after formation of anterograde flow in patients with acute ischemic stroke: preliminary experience and short term follow-up results. Clin Neurol Neurosurg. 2012;114:1316–9.CrossRefPubMedGoogle Scholar
  98. 98.
    Seo JH, Jeong HW, Kim ST, Kim EG. Adjuvant tirofiban injection through deployed solitaire stent as a rescue technique after failed mechanical thrombectomy in acute stroke. Neurointervention. 2015;10:22–7.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Marmur JD, Poludasu S, Agarwal A, Manjappa N, Cavusoglu E. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention. J Invas Cardiol. 2008;20:53–8.Google Scholar
  100. 100.
    Wang Y, Zhao X, Liu L, Soo YO, Pu Y, Pan Y, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in china: the chinese intracranial atherosclerosis (cicas) study. Stroke. 2014;45:663–9.CrossRefPubMedGoogle Scholar
  101. 101.
    Kim JS, Nah HW, Park SM, Kim SK, Cho KH, Lee J, et al. Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease. Stroke. 2012;43:3313–8.CrossRefPubMedGoogle Scholar
  102. 102.
    Castillo J. Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment. Cerebrovasc Dis. 1999;9(Suppl 3):1–8.CrossRefPubMedGoogle Scholar
  103. 103.
    Hussein HM, Saleem MA, Qureshi AI. Rates and predictors of futile recanalization in patients undergoing endovascular treatment in a multicenter clinical trial. Neuroradiology. 2018;60:557–63.CrossRefPubMedGoogle Scholar
  104. 104.
    Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA. 2016;316:1279–88.CrossRefPubMedGoogle Scholar
  105. 105.
    Wunderlich MT, Goertler M, Postert T, Schmitt E, Seidel G, Gahn G, et al. Recanalization after intravenous thrombolysis: does a recanalization time window exist? Neurology. 2007;68:1364–8.CrossRefPubMedGoogle Scholar
  106. 106.
    von Kummer R, Holle R, Rosin L, Forsting M, Hacke W. Does arterial recanalization improve outcome in carotid territory stroke? Stroke. 1995;26:581–7.CrossRefGoogle Scholar
  107. 107.
    Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: part i—pathophysiological and pharmacological features. Neurosurgery. 2000;46:1344–59.CrossRefPubMedGoogle Scholar
  108. 108.
    Jeong HG, Kim BJ, Yang MH, Han MK, Bae HJ, Lee SH. Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment. Neurology. 2016;87:996–1002.CrossRefPubMedGoogle Scholar
  109. 109.
    Zhao W, Che R, Shang S, Wu C, Li C, Wu L, et al. Low-dose tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular thrombectomy. Stroke. 2017;48:3289–94.CrossRefPubMedGoogle Scholar
  110. 110.
    Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein ib, vi, and iib/iiia blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115:2323–30.CrossRefPubMedGoogle Scholar
  111. 111.
    Kellert L, Hametner C, Rohde S, Bendszus M, Hacke W, Ringleb P, et al. Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. Stroke. 2013;44:1453–5.CrossRefPubMedGoogle Scholar
  112. 112.
    Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase iii trial: Abciximab in emergency treatment of stroke trial (abestt-ii). Stroke. 2008;39:87–99.CrossRefPubMedGoogle Scholar
  113. 113.
    Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, et al. Effects of unfractionated heparin and glycoprotein iib/iiia antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol. 2007;27:1850–6.CrossRefPubMedGoogle Scholar
  114. 114.
    Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, et al. Sex differences in major bleeding with glycoprotein iib/iiia inhibitors: results from the crusade (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the acc/aha guidelines) initiative. Circulation. 2006;114:1380–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Neurology, Beijing Tiantan HospitalCapital Medical UniversityBeijingPeople’s Republic of China
  2. 2.Department of Interventional Neurology, Beijing Tiantan HospitalCapital Medical UniversityBeijingPeople’s Republic of China
  3. 3.China National Clinical Research Center for Neurological DiseasesBeijingPeople’s Republic of China
  4. 4.Center of StrokeBeijing Institute for Brain DisordersBeijingPeople’s Republic of China

Personalised recommendations